Type 2 Diabetes

Dr. Paul Thompson reflects on how advances in diabetes management have bled over into the field of cardiology and offers perspective on why he believes staying abreast of these advances is an integral part of being a cardiologist today.

Bertram Pitt, MD, offers perspective on how he interprets data from both FIDELIO-DKD and FIGARO-DKD inform the use of finerenone in patients with diabetes and chronic kidney disease.

Results of a post hoc analysis of the TWILIGHT trial provide insight into the effects of ticagrelor monotherapy compared to dual therapy with aspirin in patients with concomitant CKD and diabetes.

Results of FIGARO-DKD were presented at ESC Congress 2021 and, combined with FIDELIO-DKD data, demonstrate the ability of finerenone to provide benefit across the spectrum of eGFR.

Sexual dysfunction in men was related to clinical factors, including erectile dysfunction, while women reported low emotional well-being and symptoms of anxiety.

Now that the agent shows benefit in mitigating comorbid risks, the expert advocates for more timely diagnoses and treatment initiation.

Deepak Bhatt, MD, discusses a presentation he gave at ESC Congress 2021 on SGLT2, 1/2 inhibition and reflects on the potential for sotagliflozin to receive approval from the FDA based on data from SOLOIST-WHF and SCORED.

Professor Bertram Pitt discusses the results of FIGARO-DKD, what they add when combined with FIDELIO-DKD, and future research priorities moving forward in a Q&A with Practical Cardiology.

August's month in review features a pair of FDA approvals, new guidance on screening for gestational diabetes and T2D, a 3-part video series, and news on COVID-19, glucose control, and vitamin D levels.

Incidence of death from cardiovascular causes was lower in the finerenone group (458 of 3686 patients) compared to the placebo group (519 of 3666 patients).

FIGARO-DKD concluded use of finerenone was associated with a 13% reduction in the primary outcome, which investigators purport demonstrates the benefit of finerenone use in a population with milder chronic kidney disease than those included in FIDELIO-DKD.

The updated USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 - 75 years with conditions including overweight or obesity.

The US Preventive Services Task Force has issued a B-graded recommendation statement lowering their recommended age for screening for type 2 diabetes from 40 to 35 years.

Data from the SEARCH for Diabetes in Youth Study suggests the prevalence of type 1 diabetes among youths have increased by nearly 50% from 2001-2017 and prevalence of type 2 diabetes increased by more than 95% during the same period.

New data suggests patients with a history of diabetes, hypertension, or cardiovascular disease were at increased risk of worsening hypoxemia compared to their counterparts without these conditions.

A new meta-analysis by investigators from Johns Hopkins details the prevalence of UACR testing in patient populations at increased risk of albuminuria, suggesting less than 40% of patients with diabetes underwent UACR testing and this figure dropped to less than 5% among patients with hypertension.

A review article details the prevalence and impact of sleep disorders in patients with type 2 diabetes as well as providing an overview current treatment options and research needs.

Most common factor for hospitalizations of T2D include cardiac disorder, infections and infestations, and nervous system disorders.

An analysis of registry data from more than 2.4 million births in Denmark suggests those born to mothers with diabetes were 39% more likely to experience high refractive error before turning 25 years old.

A recent study published in JAMA details increasing rates of gestational diabetes among first-time mothers in the US from 2011-2019, with rates increasing across all racial/ethnic subgroups examined in the 12 million person analysis.

A substudy of a prospective observational study performed at a hospital in Italy details potential associations of vitamin D levels with BMI and blood glucose and severity of COVID-19.

Eli Lilly and Company announced the FDA has expanded the label of insulin lispro-aabc injection (Lyumjev) to allow for administration via insulin pumps.

The treatment controls blood sugar levels after meals in adults with type 1 and type 2 diabetes.

The study notes the importance of follow-up monitoring of sleep apnea in patients with IH.

An analysis of data from a national health database in South Korea suggests increased BMI variability was linked to a 66% greater risk of mortality and a 19% greater risk of heart attack and stroke in patients with chronic kidney disease.